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Disclaimer: Due to the rapidly evolving nature of this outbreak, 
and in the interests of rapid dissemination of reliable, actionable 
information, this paper went through expedited peer review. 
Additionally, information should be considered current only at the 
time of publication and may evolve as the science develops. On 
February 11, 2020, the World Health Organization renamed the 
virus COVID-19.
INTRODUCTION
On March 10, 2020, the World Health Organization (WHO) 
declared a global pandemic due to widespread infection of 
the novel coronavirus COVID-19 (coronavirus disease 2019) 
University of California, San Diego, Department of Emergency Medicine, San Diego, 
California
Introduction: On March 10, 2020, the World Health Organization declared a global pandemic due to 
widespread infection of the novel coronavirus 2019 (COVID-19). We report the preliminary results of a 
targeted program of COVID-19 infection testing in the ED in the first 10 days of its initiation at our institution.  
   
Methods: We conducted a review of prospectively collected data on all ED patients who had targeted testing 
for acute COVID-19 infection at two EDs during the initial 10 days of testing (March 10-19, 2020). During this 
initial period with limited resources, testing was targeted toward high-risk patients per Centers for Disease 
Control and Prevention guidelines. Data collected from patients who were tested included demographics, 
clinical characteristics, and test qualifying criteria. We present the data overall and by test results with 
descriptive statistics. 
Results: During the 10-day study period, the combined census of the study EDs was 2157 patient 
encounters. A total of 283 tests were ordered in the ED. The majority of patients were 18-64 years of age, 
male, non-Hispanic white, had an Emergency Severity Index score of three, did not have a fever, and were 
discharged from the ED. A total of 29 (10.2%) tested positive. Symptoms-based criteria most associated with 
COVID-19 were the most common criteria identified for testing (90.6%). All other criteria were reported in 
5.51–43.0% of persons being tested. Having contact with a person under investigation was significantly more 
common in those who tested positive compared to those who tested negative (63% vs 24.5%, respectively). 
The majority of patients in both results groups had at least two qualifying criteria for testing (75.2%).
Conclusion: In this review of prospectively collected data on all ED patients who had targeted testing for 
acute COVID-19 infection at two EDs in the first 10 days of testing, we found that 10.2% of those tested were 
identified as positive. The continued monitoring of testing and results will help providers understand how 
COVID-19 is progressing in the community. [West J Emerg Med. 2020;21(3)XX-XX.] 
internationally. Due to a number of challenges, including the 
unpredictable availability of testing materials, testing for the 
acute infection was sporadic in the early days of the epidemic in 
the United States. As a result, testing in emergency departments 
(ED) has been limited and only began to increase following 
the WHO declaration. We report the preliminary results of a 
targeted program of COVID-19 infection testing in the ED in 
the first 10 days of its initiation at our two institutional EDs.    
 
METHODS
We conducted a review of prospectively collected data on 
all ED patients who had targeted testing for acute COVID-19 
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infection at two EDs, located at an urban teaching hospital 
(ED census approximately 50,000/year), and academic 
quaternary medical center (ED census approximately 35,000/
year) in San Diego, California, within the same healthcare 
system during the initial 10 days of testing (March 10-19, 
2020). During this initial period with limited resources, 
testing was targeted toward high-risk patients with the 
following known criteria as per Centers for Disease Control 
and Prevention (CDC) guidelines: patients presenting with 
symptoms concerning for COVID-19 infection (fever AND 
cough or shortness of breath); travel within 14 days to 
countries with high rates of infection (at that time China, Iran, 
Italy, Japan, and South Korea); or risk factors for infection 
complications (including age or co-morbid conditions); or 
the patient was a healthcare worker who could potentially 
expose others at risk. Test ordering was at the discretion of the 
attending emergency physician based on these criteria. 
We used the ePLex SARS-CoV-2 test, which detects virus 
particles in clinical samples collected with a nasopharyngeal 
swab. The test was conducted under the GenMark Diagnostics 
platform with a US Food and Drug Administration emergency-
use authorization, and evaluated in-house at our institution’s 
clinical laboratory. Data collected from patients who were 
tested included demographics, clinical characteristics, and test 
qualifying criteria. Demographics included age group (<18, 18-
64, and 65+), gender, and race/ethnicity, Clinical characteristics 
included Emergency Severity Index (ESI) score, fever present 
on arrival to ED (yes/no), ED disposition, and COVID-19 test 
results. Test qualifying criteria included symptoms, contact with 
a person under investigation, a healthcare worker with potential 
contact of an infected person, recent travel to high-risk areas, 
and high-risk comorbidities. Patient demographics, clinical 
characteristics and test qualifying questions are presented 
overall and by test results with descriptive statistics. 
Positive (n = 29) Negative (n = 254) Total (n = 283)
Characteristics Number (%) Number (%) Number (%)
Age group
<18 0 (0.0) 2 (0.8) 2 (0.7)
18-64 25 (86.2) 211 (83.1) 236 (83.4)
65+ 4 (13.8) 41 (16.1) 45 (15.9)
Gender
Female 13 (44.8) 120 (47.2) 133 (47.0)
Male 16 (55.2) 134 (52.8) 150 (53.0)
Race/ethnicity
Hispanic 4 (13.8) 47 (18.5) 51 (18.0)
NH White 20 (69.0) 141 (55.5) 161 (56.9)
NH Black 0 (0.0) 13 (5.1) 13 (4.6)
NH Asian/PI 2 (6.9) 25 (9.8) 27 (9.5)
Other/Mixed/Unknown 3 (10.3) 28 (11.0) 31 (11.0)
Emergency severity index
Resuscitation 0 (0.0) 1 (0.4) 1 (0.4)
Emergency 3 (10.3) 46 (18.3) 49 (17.5)
Urgent 14 (48.3) 120 (47.8) 134 (47.9)
Less urgent 11 (37.9) 72 (28.7) 83 (29.6)
Non-urgent 1 (3.4) 12 (4.8) 13 (4.6)
Fever present on arrival
Yes 2 (6.9) 25 (9.9) 27 (9.6)
No 27 (93.1) 227 (90.1) 254 (90.4)
ED Disposition
Admit/Transfer 6 (20.7) 75 (29.5) 81 (28.6)
Discharged/AMA/Eloped 23 (79.3) 179 (70.5) 202 (71.4)
Note: Missing measures included 2 temperature and 3 Emergency Severity Index values for patients with negative COVID-19 results.
COVID-19, coronavirus 2019; NH, non-Hispanic; PI, Pacific Islander; ED, emergency department; AMA, against medical advice.
Table 1. Patient demographics and clinical characteristics by test results for patients who were tested for COVID-19 during the first 10 days of 
testing.
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RESULTS
During the 10-day study period, the combined census of the 
study EDs was 2157 patient encounters. This was a decrease of 
about 21.2% from the same time period in 2019. A total of 283 
tests were ordered in the ED. Patient demographics and clinical 
characteristics are presented in Table 1. The majority of patients 
were 18–64 years of age, male, non-Hispanic white, had an 
ESI score of three, did not have a fever, and were discharged 
from the ED. A total of 29 (10.2%) tested COVID-19 positive. 
Among these, characteristics paralleled the overall distribution 
of all patients that were tested. The majority (23/29, 79.3%) of 
COVID-19 positive patients were also discharged, left against 
medical advice, or eloped, while those who were admitted or 
transferred (6/29) were split between patients 18-64 years of 
age and 65 or older (three from each group). There have been 
no deaths in our cohort of COVID-19 patients.
 The test qualifying criteria are reported in Table 2. 
Symptoms-based criteria most associated with COVID-19 were 
the most common criteria identified for testing (90.6%). All 
other criteria were reported in 43.0% or less of patients. Travel 
was the least common qualifying response (5.5%). We found 
only small differences in test qualifying criteria by symptoms 
and being a healthcare worker, between patients testing positive 
and negative. Having contact with a person under investigation 
was significantly more common in those testing positive vs 
negative (63% vs 24.5%, respectively). The majority of patients 
in both results groups had at least two qualifying criteria for 
testing (75.2% overall).
DISCUSSION
COVID-19 infection is caused by a novel severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), a new 
human pathogen first identified in Wuhan, Hubei Province, 
China, in December 2019 that has led to worldwide pandemic.  
COVID-19 is similar to other zoonotic coronaviruses, named 
for the so-called “spike proteins” that appear like a crown on 
these enveloped viruses. A number of coronavirus types are 
“common cold” pathogens, while certain novel strains have led 
Positive (n = 27) Negative (n = 208) Total (n = 235)
Qualifying questions Number (%) Number (%) Number (%)
Symptoms
Yes 25 (92.6) 188 (90.4) 213 (90.6)
No 2 (7.4) 20 (9.6) 22 (9.4)
Contact with person under investigation
Yes 17 (63.0) 49 (23.6) 66 (28.1)
No 10 (37.0) 159 (76.4) 169 (71.9)
Healthcare worker
Yes 7 (25.9) 51 (24.5) 58 (24.7)
No 20 (74.1) 157 (75.5) 177 (75.3)
Foreign travel to COVID endemic country
Yes 3 (11.1) 10 (4.8) 13 (5.5)
No 24 (88.9) 198 (95.2) 222 (94.5)
Comorbidities
 Yes 8 (29.6) 93 (44.7) 101 (43.0)
 No 19 (70.4) 115 (55.3) 134 (57.0)
Total number of confirmed qualifying questions
  0 0 (0.0) 3 (1.4) 3 (1.3)
  1 4 (14.8) 51 (24.5) 55 (23.4)
  2 15 (55.6) 123 (59.1) 138 (58.7)
  3 7 (25.9) 30 (14.4) 37 (15.7)
  4 0 (0.0) 1 (0.4) 1 (0.4)
  5 1 (3.7) 0 (0.0) 235 (0.4)
Note: Questions were asked for 235 (83.0%) of the 283 patients who received COVID-19 testing. 
COVID-19, coronavirus 2019.
Table 2. COVID-19 test qualifying question for patients who were tested for COVID-19 during the first 10 days of testing (n = 235/283 tested).
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to outbreaks of respiratory diseases (SARS-CoV-1, Middle East 
respiratory syndrome (MERS-CoV).
Worldwide, as of March 27, 2020, there have been nearly 
586,000 confirmed cases of COVID-19 resulting in 26,865 
deaths. In the US there have been over 97,000 cases with 
over 1,400 deaths.1 For the majority of infections, COVID-19 
results in a mild respiratory illness.2 However, a significant 
number result in serious morbidity and death, associated with 
advanced age and co-morbidities including hypertension, 
diabetes, and immunosuppression.3
The first case of COVID-19 confirmed in the US was 
reported in January 2020.4 The early stages of the response to 
COVID-19 in the US was hampered by multiple challenges 
and issues, particularly availability of diagnostic testing for the 
novel coronavirus.5 As a result, testing has been limited with 
specific criteria recommended by the CDC including severity of 
disease, such as requiring hospitalization, recent travel, or risk 
factors for significant morbidity and mortality.6 In response, a 
number of innovative approaches have been piloted to assess 
patients for the disease.7
As of mid-March, the CDC reported 7038 confirmed or 
presumptive positive coronavirus tests, with a total number of 
specimens tested by CDC labs of 4484 and US public health 
laboratories of 33,340.8,9 In our study, in the initial 10 days of 
in-house testing for ED patients meeting criteria for diagnostic 
evaluation, we report a 10.2% incidence rate of 283 tests 
conducted. The true incidence rate of COVID-19 in the US is 
unknown and will continue to be unclear until the ability for mass 
testing becomes available. 
LIMITATIONS
First, we report only preliminary data from the ED for an 
initial brief period (10 days). We believe this is one of the first 
reports of the results of in-house novel coronavirus testing in the 
emergency setting. Second, our study was conducted at a single 
healthcare institution with two EDs in one metropolitan region 
and thus our results may not reflect the conditions or expected 
findings in other communities or hospital EDs. Finally, this report 
is in the early stages of the pandemic in the US and in particular 
in the very early stages of testing availability in the US. It is likely 
that with further expansion of testing access and availability, new 
information and insights into this pandemic and its impact on our 
healthcare resources and communities will be discovered.
CONCLUSION
In this review of prospectively collected data on all ED 
patients who had targeted testing for acute COVID-19 infection 
at two EDs in the first 10 days of testing, we found over 10% 
of those tested were identified as positive. Nearly all of these 
patients did not have a fever when they arrived to the ED. 
However, a history of viral infection symptoms was the most 
common criteria for testing. The continued monitoring of testing 
and results will help providers understand how COVID-19 is 
progressing in the community and identify patient characteristics 
most suggestive of acute infection. This will help with public 
health surveillance and ongoing efforts to reduce the transmission 
of the virus and “flatten the curve.” 
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